Amgen Inc
NASDAQ:AMGN

  • LAST PRICE
    294.5300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    293.0000/ 2
  • Ask / Lots
    293.7700/ 1
  • Open / Previous Close
    --- / 294.5300
  • Day Range
    ---
  • 52 Week Range
    260.6800
    346.8500
  • Volume
    5,464

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
AMGN
Amgen Inc
158.3B
37.7x
-0.22%
GILD
Gilead Sciences Inc
112.4B
1,073.8x
+1.53%
BMY
Bristol-Myers Squibb Co
119.4B
-16.4x
+4.90%
AZN
AstraZeneca PLC
204.4B
31.6x
+17.52%
SNY
Sanofi SA
123.8B
25.8x
+4.55%
HLN
Haleon PLC
43.3B
29.3x
---
As of 2024-11-25

Company Information

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Contact Information

Headquarters
One Amgen Center DriveTHOUSAND OAKS, CA, United States 91320
Phone
805-447-1000
Fax
805-447-1010

Executives

Chairman of the Board, President, Chief Executive Officer
Robert Bradway
Chief Financial Officer, Executive Vice President
Peter Griffith
Executive Vice President, Chief Technology Officer
David Reese
Executive Vice President, Research and Development, and Chief Scientific Officer
James Bradner
Executive Vice President, General Counsel, Secretary
Jonathan Graham

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$158.3B
Revenue (TTM)
$32.5B
Shares Outstanding
537.5M
Dividend Yield
3.06%
Annual Dividend Rate
9.0000 USD
Ex-Dividend Date
11-18-24
Pay Date
12-09-24
Beta
0.56
EPS
$7.82
Book Value
$11.64
P/E Ratio
37.7x
Price/Sales (TTM)
4.9
Price/Cash Flow (TTM)
16.1x
Operating Margin
19.91%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.